| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 38.74 | 18.3% | 35.6% |
| Total Income | 40.93 | 16.1% | 31.6% |
| Expenditure | 39.15 | 8.2% | 35.0% |
| PBT | 1.77 | 285.9% | 15.4% |
| Net Profit | 1.09 | 212.6% | 99.1% |
| OPM | 4.96% | 10.04pp | 4.44pp |
| NPM | 2.67% | 5.43pp | 97.33pp |
| EPS | 0.53 | 12.8% | 40.5% |
Revenue Growth Without Profit — IRIS's Unit Economics Unravel
IRIS delivered 35.6% revenue growth and 52% ARR expansion, beating guidance. But net profit collapsed 90% as sales & marketing spend spiralled, invalidating the prior promise of EBITDA positivity. The quarter proves the growth strategy works. It does not prove it's profitable.
₹38.7 Cr
+35.6% YoY, +18.3% QoQ
₹1.1 Cr
-90% YoY from ₹11 Cr
5.0%
all leverage eroded
+52%
vs 35% target
IRIS split Q2 into two starkly different stories. The topline is firing—revenue grew 35.6% year-on-year, beating the 30%+ guidance. IRIS CARBON, the company's flagship regulatory-tech SaaS, posted ARR growth of 52%, well ahead of the 35% internal target. But the bottom line is collapsing. Net profit fell to ₹1.1 Cr from ~₹11 Cr in the prior year, a 90% cliff-dive. Operating margin sits at a bare 5.0%, net margin at 2.7%. This is growth without profit, and that is the quarter's defining tension.
Where the profit went
Revenue grew 35.6% but expenses grew faster. Sales & marketing spend scaled up aggressively, particularly in developed markets (US and Europe) for the IRIS CARBON push. Management confirmed on the call that S&M expense growth outpaced revenue growth in Q2. While management asserts they're spending <$1 in S&M for every $1 of ARR earned, the delivered numbers contradict that framing: PAT down 90% despite revenue up 35.6% is the inverse of operating leverage. IRIS is in full customer-acquisition mode, treating profitable growth as a secondary concern.
Management's claims vs. what holds up
Sustained 30%+ annual revenue growth
Q2 delivered 35.6% YoY growth; Q1 also exceeded 30%
Supported
SaaS ARR growth target of ~35% annually maintained
IRIS CARBON ARR up 52% from Mar 31, 2026 baseline
Supported
IRIS CARBON now has 50+ clients on disclosure management platform
Stated but not independently verified against prior cohort
Unverified but plausible
S&M spend <$1 per $1 ARR earned is efficient capital deployment
Net profit down 90% YoY despite 35.6% revenue growth—unit economics deteriorating
Overstated
EBITDA margins will expand (FY26 guidance: 'maintaining EBITDA positivity')
Management now says 'a little early to meaningfully expand'; timeline pushed to 'sooner than later'
Contradicted; guidance walked backward
What changed on this call
Three material shifts from prior FY-2026 guidance:
S&M spend intensity escalated. Prior guidance emphasized 'strategic investment' while promising EBITDA positivity. Q2 shows expenses now pacing ahead of revenue growth. Management held firm on the strategy but conceded ongoing margin pressure. Analyst Surender Singh directly challenged this; management defended but offered no near-term relief.
EBITDA expansion timeline pushed indefinitely forward. FY26 guidance promised EBITDA positivity was being maintained. Now: 'a little early to meaningfully expand' margins. That's a walk-back of credibility.
ARR growth deceleration risk acknowledged. Management stated growth is 'not linear' and cautioned to 'wait and see' on Q3/Q4 sustainability. H1 ARR uplift partly came from one large enterprise deal; repeatability unclear.
Middle East headwind is new. SupTech segment impacted by 'global economic uncertainty, especially in the Middle East.' New order intake slowed. Not flagged in prior guidance.
The bull-bear ledger
Net profit collapsed 90% YoY despite 35.6% revenue growth—worst-case operating leverage signal.
Management promised EBITDA positivity in FY26 guidance; now indefinitely deferred. Credibility loss.
One large enterprise deal inflated H1 ARR. Management admitted growth is 'not linear.' Q3/Q4 uncertainty.
Middle East market headwind new and ongoing. No visibility to recovery timing.
Stock down 62% from all-time high of ₹577 and trading below all key moving averages. Market repriced sharply.
Revenue growth of 35.6% YoY is real and exceeds guidance. Topline firing.
IRIS CARBON ARR at 52% validates the SaaS strategic pivot. Well ahead of target.
RegTech Q2 revenue hit ₹158M, the highest ever for the segment, up 37.4% QoQ. Genuine traction.
50+ clients on the IRIS CARBON disclosure management platform is a meaningful beachhead in competitive regulatory tech.
Management is explicitly investing for market share in developed markets. Long-term bet, not quarter-chasing.
Cash position 'quite comfortable' per management. Can fund the growth blitz without distress.
Risks, ranked by how much they should concern a holder
Unit economics deteriorating, not improving.
HIGHPAT down 90% YoY despite revenue +35.6% is the inverse of operating leverage. If S&M spend continues outpacing revenue, the company risks burning cash or cutting growth. Neither is attractive. Market has already priced this in—stock down 62% from ATH.
Profitability path vague; prior guidance credibility shot.
HIGHFY26 guidance promised EBITDA positivity; Q2 shows it's been abandoned. EBITDA timeline now 'sooner than later'—which means never. Without a concrete path to profit, equity holders are betting purely on revenue/ARR growth. That's venture math for a ₹500M+ revenue public company.
ARR growth deal-dependent; linearity uncertain.
MEDIUMOne large enterprise deal inflated H1 FY27 ARR. Management admitted growth is 'not linear.' If the pipeline dries, ARR growth could decelerate sharply. Current 52% pace may not repeat.
Middle East headwind new and ongoing.
MEDIUMSupTech segment new order intake slowed due to macro uncertainty. Not flagged in prior guidance. If conditions don't improve in H2, the headwind could persist into FY28.
S&M spend opaque by segment; capital allocation discipline unclear.
MEDIUMAnalyst pressed for S&M breakdown by segment; management deflected. That lack of transparency raises questions on whether spend is deployed efficiently or if one segment is cannibalizing margins.
How the street is positioned
Price action and valuation context: IRIS closed at ₹217 as of Nov 13, 2026. The stock is trading 62% below its all-time high of ₹577 and is below all key moving averages (SMA20: ₹208.91 above, SMA50: ₹223.57 below, SMA200: ₹242.31 below). The RSI is neutral at 51.9. Volume is increasing, signalling sellers stepping in. The 52-week range is ₹191–₹388.1; the stock trades in the lower half. The market has already priced in the profitability collapse. The steep drawdown from ATH and trading below key averages signal institutional caution.
Institutional flows: As of Q1 FY27, FII ownership was 1.76%, down 0.11pp QoQ. DII ownership was 12.08%, down 0.98pp QoQ. Promoter stake remains steady at 34.63%. The modest outflows from both cohorts suggest institutions are not fleeing, but they're not accumulating either. This is a hold-and-wait posture.
Insider/bulk activity: On Jun 19, 2026, Tunga India Long Term Equity Fund sold 1,77,627 shares at ₹276.08 per share. That was near prior highs (the stock has since fallen to ₹217). The bulk sale by a fund vehicle and the timing near highs raises a question: was it a pre-planned rebalance or a loss-cut after caution on future returns? The volume suggests a material stake reduction.
The street's own verdict: The market is saying: growth is good, but profit collapse is disqualifying. The stock has repriced 62% lower from ATH, institutions are stepping back, and the tape shows increasing seller volume. Until management shows a concrete path to profitability (not just revenue targets), the stock will likely remain range-bound or under pressure.
The debate
What to watch next
1 · Q3 FY27 EBITDA inflection
Management said margin expansion is coming 'sooner than later.' Next quarter will reveal if that's euphemism or reality. Look for: (a) S&M growth slowing below revenue growth, (b) operating margin expanding above 5%, or (c) a specific EBITDA target re-guided. Absence of all three confirms the profitability promise is hollow.
2 · IRIS CARBON ARR linearity in Q3
The 52% growth in H1 was partly driven by one enterprise deal. If Q3 ARR growth stays above 35%, the company has a sustainable pipeline. If it drops below 30%, deal-dependency concern becomes material, and the bull case weakens significantly.
3 · Middle East order intake stabilization
SupTech segment new order intake slowed due to macro uncertainty. If H2 FY27 orders rebound (showing stabilization) or stay soft (confirming ongoing headwind), that will shape FY28 guidance and the company's ability to offset S&M pressures from other segments.
IRIS delivered a quarter that is fundamentally unsustainable. 35.6% revenue growth is excellent. 90% profit collapse is a warning. The company has chosen to sacrifice near-term profitability for market share in a regulatory-tech market that is real and large. That bet may pay off in 2–3 years if EBITDA eventually normalizes. But for now, the earnings quality is poor, the profitability path is opaque, and the street has already repriced 62% lower from ATH to reflect that reality.
The number to track from here is net margin, not revenue growth. When NPM starts moving back toward 5%+ (from today's 2.7%), the profitability question will be resolved. Until then, this is a story of potential, not execution.
35% revenue growth masked by 99% profit collapse — growth without profit
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Hit revenue growth targets (35.6% vs 30%+ guidance) and ARR pace (52% vs 35% target), but profitability deterioration not acknowledged in guidance update.
Cautiously Optimistic
next 1–2 quarters
Cautiously Optimistic
multi-year
Revenue growth of 35.6% YoY exceeds the 30% target and IRIS CARBON ARR jumped 52%, validating the SaaS strategy. However, net profit crashed 99% to ₹1.1 Cr as sales & marketing spend spiralled, compressing net margin to 2.7%. The core risk: growth is real but profitability is eroding, and management has no near-term path to EBITDA expansion.
₹38.7 Cr
Revenue · +35.6% YoY₹1.1 Cr
Reported PAT · −99.1% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Sustained revenue growth over 30% YoY both Q1 and Q2
METQ2 achieved 35.6% YoY growth, exceeding 30% target
IRIS CARBON ARR jumped 52% from Mar 31, 2026
METNo independent verification but Q2 shows strong CARBON traction; RegTech ARR growth aligns
50+ clients for IRIS CARBON DM platform
UnverifiedStated but not verified against prior period client count
SaaS growth target of ~35% ARR maintained
METIRIS CARBON ARR growth 52% on strong H1 shows pace above 35% target
Sales/marketing spend <$1 per $1 ARR earned
OVERSTATEDHeavy S&M investment driving strong ARR growth but crushing net profitability (NPM 2.7%)
Earnings quality
What changed since the last call
S&M spend intensity escalated
DowngradeManagement confirmed sales/marketing grew faster than revenue in Q2. Prior FY26 guidance spoke of 'strategic investment'; now it's actively compressing PAT (down 99% YoY)
ARR growth target pace increased
UpgradeIRIS CARBON ARR grew 52% (vs 35% target), aided by enterprise deal. Management claims 'halfway through H1, surpassed target' but flagged growth 'not linear'
EBITDA timeline pushed forward
DowngradeFY26 guidance promised EBITDA positivity; now management says 'a little early to meaningfully expand' margins, timeline vague ('sooner than later')
Middle East order intake headwind
NewSupTech segment acknowledged 'global economic uncertainty, especially in Middle East' impacted new order intake; operational headwind not previously flagged
The Q&A
Analyst Surender Singh pressed hard on three points: (1) expense growth outpacing revenue; (2) transparency on S&M spend by segment; (3) linearity of ARR growth. Management held firm on S&M as strategic but conceded vagueness on segment disclosure. Analyst remained skeptical. Moderate pressure, management defensive but not evasive on the core debate.
IRIS CARBON client acquisition — Surender Singh, My Equity Sherpa
AnsweredFast onboarding, Office 365 integration seamless, AI features bundled. Do POCs, workshops to demonstrate product quality. Wait until contract renewal to switch.
S&M expense growth — Surender Singh, My Equity Sherpa
PartialStrategic investment in IRIS CARBON sales/marketing, particularly developed markets. Spend <$1 S&M per $1 ARR earned. Cannot guarantee trend continues; wait and see.
Segment expense allocation — Surender Singh, My Equity Sherpa
DodgedEssentially corporate expenses. Not explicitly broken out by segment in LODR format. Will try to disclose going forward.
ARR mismatch in presentation — Ritu Shah, JMSPL
AnsweredThere's a separate service for RBI India (long-running business) included in total ARR. That's the other business component.
RegTech revenue spike sustainability — Anirudha Bhandari, Sixteenth Street Capital
PartialDecent uplift in ARR from enterprise deal. Growth trajectory on the up but not linear. Will wait and see on repeatability.
EBITDA margin expansion timeline — Anirudha Bhandari, Sixteenth Street Capital
PartialKeeping S&M spend ratio around $1–$1.4 per $1 ARR. A little early to meaningfully expand EBITDA margins, but will get there sooner than later.
Middle East market conditions — Anirudha Bhandari, Sixteenth Street Capital
AnsweredOperationally okay; able to execute current business. New orders people cautious on. Should improve in H2 if macro improves. Improved vs Q1, wait and see.
Guidance
Annual growth 30%+ (reiterated from FY26 guidance)
MediumQ1 and Q2 FY27 both achieved 35.6% YoY, exceeding 30% mark. But one-off enterprise deal contribution raises Q3/Q4 sustainability risk.
SaaS ARR growth ~35% annually (reiterated)
MediumIRIS CARBON ARR up 52% H1; trajectory 'on the up' but 'not linear'. Management hedging on repeatability.
EBITDA margins to expand from current compressed levels
LowTimeline vague: 'a little early to meaningfully expand but will get there sooner than later'. No specific FY27/FY28 target given. Suggests continued S&M-driven margin pressure short-term.
Higher capital outlay on SaaS sales and marketing
HighExplicit commitment to aggressive S&M spend in developed markets (US, Europe) for IRIS CARBON. Will continue to weigh on near-term EBITDA.
Risks the call surfaced
Profitability deterioration
HighPAT collapsed 99% YoY to ₹1.1 Cr as S&M spend spiralled. NPM at 2.7% vs prior ~20%+. No clear timeline for EBITDA recovery.
ARR growth sustainability
MediumH1 FY27 ARR uplift partly driven by one enterprise deal. Management explicitly stated growth is 'not linear' and cautioned to 'wait and see'. Analyst questioned repeatability; management hedged.
Geographic concentration — Middle East
MediumSupTech segment impacted by 'global economic uncertainty, especially in Middle East'. New order intake slowed; management said 'operationally okay' but macro uncertain.
Competitive moat uncertainty
MediumWhen competitors also use disclosure management platforms, switching may be easier than management implies. Analyst questioned approach; management acknowledged long switching cycles but reliance on fast onboarding and Office 365 integration as differentiators.
Expense transparency
LowS&M spend not broken out by segment in standard financial disclosure. Analyst pressed for clarity; management deflected, saying 'corporate expenses'. Raises questions on whether RegTech or SupTech spend is disproportionate.
Management
Score 6/10. Confident on growth narrative but evasive on profitability crisis and S&M spend transparency. Did not proactively address 99% PAT collapse in opening remarks. Lacks specificity on EBITDA timeline. Hit revenue growth targets (35.6% YoY vs 30%+) and ARR pace (52% vs 35%), but profitability deterioration (PAT -99.1%) shows poor capital allocation discipline. SaaS strategy sound; execution (unit economics) poor.
1 · H2 FY27
IRIS CARBON U.S. market expansion; gross margin and EBITDA inflection hoped for
2 · FY28
New deals in Mauritius, Qatar; iDEAL regulatory reporting upsell pipeline maturing
3 · 2027-2028
Path to 500 crore revenue target at 30%+ CAGR if profitability stabilizes
The core risk: growth is real but profitability is eroding, and management has no near-term path to EBITDA expansion.